Objective: To explore baseline risk factors for productivity loss and work disability over 5 years in patients with early, active RA.
Patients and methods: In the FIN-RACo trial, 195 patients with recent onset RA were randomised to receive either a combination of DMARDs with prednisolone or a single DMARD for 2 years. At baseline, 162 patients were working or available for work. After 5 years’ follow up, data on sick leave and retirement were obtained from social insurance registers or case records. The cumulative duration of sick leaves and RA related disability pensions was counted for each patient. To analyse predictors of productivity loss, the patients were divided into four groups according to duration of work disability per patient year.
Results: Patient’s and physician’s global assessment of RA severity ⩾50 and HAQ score ⩾1.0 were risk factors for extension of productivity loss (OR (95% (CI) 1.77 (1.00 to 3.16), 1.85 (1.03 to 3.32), and 1.78 (1.01 to 3.14), respectively). Additional risk factors were low education level (2.40 (1.18 to 4.88)) and older age (1.03 (1.00 to 1.06)); combination treatment was a protective factor (0.59 (0.35 to 0.99)).
Conclusion: At baseline, the risk of future productivity loss is best predicted by education level, age, global assessments of RA severity, and HAQ score.
- CI, confidence interval
- DMARD, disease modifying antirheumatic drug
- ESR, erythrocyte sedimentation rate
- HAQ, Health Assessment Questionnaire
- HR, hazard ratio
- OR, odds ratio
- RA, rheumatoid arthritis
- early rheumatoid arthritis
- productivity loss
- follow up study
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.